Prestige Consumer Healthcare Acquires LaCorium Health for $150M, Reports FY26 Results & Positive FY27 Outlook
PBH is trading near its 52-week low of $49.28 (5.1% above the low).
Summary
Prestige Consumer Healthcare announced a $150 million acquisition of Australian therapeutic skin care leader LaCorium Health, alongside reporting mixed fiscal 2026 results and issuing a positive financial outlook for fiscal 2027 and the medium term.
Key Events · Corporate Governance and Compliance · PBH
-
Acquires LaCorium Health for $150M
Prestige Consumer Healthcare's subsidiary entered a definitive agreement to acquire LaCorium Health, an Australian therapeutic skin care leader, for approximately $150 million in cash. The transaction is expected to close in Q2 fiscal 2027.
-
Reports Fiscal Year 2026 Results
The company reported fiscal year 2026 revenues of $1,088.7 million (down 4.3%) and adjusted diluted EPS of $4.38 (down 3.1%), but free cash flow increased to $246.4 million.
-
Issues Positive FY27 Outlook
For fiscal year 2027, Prestige projects revenues of $1,100-$1,121 million (1-3% organic growth), adjusted diluted EPS of $4.42-$4.51, and free cash flow of $250 million or more.
-
Announces Strong Medium-Term Targets
The company anticipates a 10% annual revenue growth CAGR and an 8% EPS growth CAGR over the next three years, with approximately $900 million in aggregate free cash flow.
Analysis · PBH · Life Sciences
Prestige Consumer Healthcare announced a definitive agreement to acquire LaCorium Health for approximately $150 million in cash. This acquisition, representing about 6.1% of the company's market capitalization, is a significant strategic expansion into the Australian therapeutic skin care market, expected to generate double-digit sales growth and $12 million in EBITDA with synergies. Concurrently, the company reported its fiscal year 2026 results, which showed a decline in revenue and adjusted EPS but an increase in free cash flow. More importantly, Prestige provided a positive outlook for fiscal year 2027, projecting organic revenue growth of 1% to 3%, increased adjusted diluted EPS, and over $250 million in free cash flow. The company also outlined ambitious medium-term targets, including a 10% annual revenue growth CAGR and an 8% EPS growth CAGR over the next three years, supported by these acquisitions and eye care capacity recovery.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBH was trading at $51.81 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $49.28 to $89.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.